Aprogen Biologics Inc. (KRX:003060)
804.00
+4.00 (0.50%)
At close: Mar 24, 2025, 3:30 PM KST
Aprogen Biologics Revenue
In the year 2024, Aprogen Biologics had annual revenue of 67.38B KRW, down -22.88%. Aprogen Biologics had revenue of 22.05B in the quarter ending December 31, 2024, a decrease of -2.88%.
Revenue
67.38B
Revenue Growth
-22.88%
P/S Ratio
1.46
Revenue / Employee
178.72M
Employees
377
Market Cap
154.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 67.38B | -19.99B | -22.88% |
Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
Dec 31, 2020 | 53.32B | 2.42B | 4.75% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,547.32B |
Celltrion | 3,557.30B |
ALTEOGEN | 102.85B |
Yuhan | 2,067.79B |
SK Biopharmaceuticals | 547.60B |
HLB Co., Ltd. | 51.92B |
Sam Chun Dang Pharm. | 210.92B |
PharmaResearch | 350.12B |